The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Structure-based discovery of opioid analgesics with reduced side effects
Open accessAbstract
Morphine is an alkaloid from the opium poppy used to treat pain. The potentially lethal side effects of morphine and related opioids—which include fatal respiratory depression—are thought to be mediated by μ-opioid-receptor (μOR) signalling through the β-arrestin pathway or by actions at other receptors. Conversely, G-protein μOR signalling is thought to confer analgesia. Here we computationally dock over 3 million molecules against the μOR structure and identify new scaffolds unrelated to known opioids. Structure-based optimization yields PZM21—a potent Gi activator with exceptional selectivity for μOR and minimal β-arrestin-2 recruitment. Unlike morphine, PZM21 is more efficacious for the affective component of analgesia versus the reflexive component and is devoid of both respiratory depression and morphine-like reinforcing activity in mice at equi-analgesic doses. PZM21 thus serves as both a probe to disentangle μOR signalling and a therapeutic lead that is devoid of many of the side effects of current opioids.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Development and testing of a general amber force field
Wang, J., Wolf, R. M., Caldwell, J. W., Kollman, P. A., & Case, D. A. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20035 · Cited by 19,506
The missing term in effective pair potentials
Berendsen, H. J. C., Grigera, J. R., & Straatsma, T. P. (1987) · The Journal of Physical Chemistry · doi:10.1021/j100308a038 · Cited by 13,345
Bayly, C. I., Cieplak, P., Cornell, W., & Kollman, P. A. (1993) · The Journal of Physical Chemistry · doi:10.1021/j100142a004 · Cited by 8,081
Comparison of multiple Amber force fields and development of improved protein backbone parameters
Hornak, V., Abel, R., Okur, A., Strockbine, B., Roitberg, A., & Simmerling, C. (2006) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.21123 · Cited by 6,914
The Behavior of Organisms: An Experimental Analysis
Jones, F. N., & Skinner, B. F. (1939) · The American Journal of Psychology · doi:10.2307/1416495 · Cited by 4,398
ChEMBL: a large-scale bioactivity database for drug discovery
Gaulton, A., Bellis, L. J., Bento, A. P., Chambers, J., Davies, M., Hersey, A., Light, Y., McGlinchey, S., Michalovich, D., Al-Lazikani, B., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr777 · Cited by 4,382
Identification of two related pentapeptides from the brain with potent opiate agonist activity
Hughes, J., Smith, T. W., Kosterlitz, H. W., Fothergill, L. A., Morgan, B. A., & Morris, H. R. (1975) · Nature · doi:10.1038/258577a0 · Cited by 3,806
Ballesteros, J. A., & Weinstein, H. (1995) · Methods in Neurosciences · doi:10.1016/s1043-9471(05)80049-7 · Cited by 2,999
Martin, W. R., Eades, C. G., Thompson, J. A., Huppler, R. E., & Gilbert, P. E. (1976) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30536-7 · Cited by 2,992
ZINC: A Free Tool to Discover Chemistry for Biology
Irwin, J. J., Sterling, T., Mysinger, M. M., Bolstad, E. S., & Coleman, R. G. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci3001277 · Cited by 2,509
Cited by
Molecular Dynamics Simulation for All
Hollingsworth, S. A., & Dror, R. O. (2018) · Neuron · doi:10.1016/j.neuron.2018.08.011 · Cited by 3,257
Trends in GPCR drug discovery: new agents, targets and indications
Hauser, A. S., Attwood, M. M., Rask-Andersen, M., Schiöth, H. B., & Gloriam, D. E. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.178 · Cited by 2,627
Poorly controlled postoperative pain: prevalence, consequences, and prevention
Gan, T. J. (2017) · Journal of Pain Research · doi:10.2147/jpr.s144066 · Cited by 1,489
Computational approaches streamlining drug discovery
Sadybekov, A. V., & Katritch, V. (2023) · Nature · doi:10.1038/s41586-023-05905-z · Cited by 1,279
Ultra-large library docking for discovering new chemotypes
Lyu, J., Wang, S., Balius, T. E., Singh, I., Levit, A., Moroz, Y. S., O’Meara, M. J., Che, T., Algaa, E., Tolmachova, K., et al. (2019) · Nature · doi:10.1038/s41586-019-0917-9 · Cited by 998
Self-citationGPCR Dynamics: Structures in Motion
Latorraca, N. R., Venkatakrishnan, A. J., & Dror, R. O. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00177 · Cited by 835
Biased signalling: from simple switches to allosteric microprocessors
Smith, J. S., Lefkowitz, R. J., & Rajagopal, S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.229 · Cited by 738
Mechanisms of signalling and biased agonism in G protein-coupled receptors
Wootten, D., Christopoulos, A., Marti-Solano, M., Babu, M. M., & Sexton, P. M. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0049-3 · Cited by 724
Structure of the µ-opioid receptor–Gi protein complex
Koehl, A., Hu, H., Maeda, S., Zhang, Y., Qu, Q., Paggi, J. M., Latorraca, N. R., Hilger, D., Dawson, R., Matile, H., et al. (2018) · Nature · doi:10.1038/s41586-018-0219-7 · Cited by 658
Self-citationG protein-coupled receptors: structure- and function-based drug discovery
Yang, D., Zhou, Q., Labroska, V., Qin, S., Darbalaei, S., Wu, Y., Yuliantie, E., Xie, L., Tao, H., Cheng, J., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00435-w · Cited by 632
Bias factor and therapeutic window correlate to predict safer opioid analgesics
Schmid, C. L., Kennedy, N. M., Ross, N. C., Lovell, K. M., Yue, Z., Morgenweck, J., Cameron, M. D., Bannister, T. D., & Bohn, L. M. (2017) · Cell · doi:10.1016/j.cell.2017.10.035 · Cited by 567
“While no calculation of the degree of bias that each of these individual compounds possess was provided, promising results were obtained showing that they could induce antinociception with fewer side effects in mice (Kruegel et al., 2016; Manglik et al., 2016).”
How Ligands Illuminate GPCR Molecular Pharmacology
Wacker, D., Stevens, R. C., & Roth, B. L. (2017) · Cell · doi:10.1016/j.cell.2017.07.009 · Cited by 560
Self-citationColvin, L. A., Bull, F., & Hales, T. G. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30430-1 · Cited by 559
TRUPATH, an open-source biosensor platform for interrogating the GPCR transducerome
Olsen, R. H. J., DiBerto, J. F., English, J. G., Glaudin, A. M., Krumm, B. E., Slocum, S. T., Che, T., Gavin, A. C., McCorvy, J. D., Roth, B. L., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0535-8 · Cited by 544
Self-citationA practical guide to large-scale docking
Bender, B. J., Gahbauer, S., Luttens, A., Lyu, J., Webb, C. M., Stein, R. M., Fink, E. A., Balius, T. E., Carlsson, J., Irwin, J. J., et al. (2021) · Nature Protocols · doi:10.1038/s41596-021-00597-z · Cited by 546
“Synthetic chemistry groups may obtain synthesis routes of the parent compound from the supplier allowing the generation of medicinal chemistry-inspired analog series 108 .”
BackgroundSelf-citationThe changing opioid crisis: development, challenges and opportunities
Volkow, N. D., & Blanco, C. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0661-4 · Cited by 522
Endogenous and Exogenous Opioids in Pain
Corder, G., Castro, D. C., Bruchas, M. R., & Scherrer, G. (2018) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-080317-061522 · Cited by 502
Self-citationG protein-coupled receptors (GPCRs): advances in structures, mechanisms and drug discovery
Zhang, M., Chen, T., Lu, X., Lan, X., Chen, Z., & Lu, S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01803-6 · Cited by 491
Structure of the D2 dopamine receptor bound to the atypical antipsychotic drug risperidone
Wang, S., Che, T., Levit, A., Shoichet, B. K., Wacker, D., & Roth, B. L. (2018) · Nature · doi:10.1038/nature25758 · Cited by 483
Self-citationThe Art and Science of Molecular Docking
Paggi, J. M., Pandit, A., & Dror, R. O. (2024) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-030222-120000 · Cited by 459
Crystal Structure of an LSD-Bound Human Serotonin Receptor
Wacker, D., Wang, S., McCorvy, J. D., Betz, R. M., Venkatakrishnan, A. J., Levit, A., Lansu, K., Schools, Z. L., Che, T., Nichols, D. E., et al. (2017) · Cell · doi:10.1016/j.cell.2016.12.033 · Cited by 457
Self-citationAn amygdalar neural ensemble that encodes the unpleasantness of pain
Corder, G., Ahanonu, B., Grewe, B. F., Wang, D., Schnitzer, M. J., & Scherrer, G. (2019) · Science · doi:10.1126/science.aap8586 · Cited by 405
Self-citationMolecular modeling in drug discovery
Adelusi, T. I., Oyedele, A.-Q. K., Boyenle, I. D., Ogunlana, A. T., Adeyemi, R. O., Ukachi, C. D., Idris, M. O., Olaoba, O. T., Adedotun, I. O., Kolawole, O. E., et al. (2022) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2022.100880 · Cited by 387
Untangling the complexity of opioid receptor function
Valentino, R. J., & Volkow, N. D. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0225-3 · Cited by 383
Impact of GPCR Structures on Drug Discovery
Congreve, M., de Graaf, C., Swain, N. A., & Tate, C. G. (2020) · Cell · doi:10.1016/j.cell.2020.03.003 · Cited by 375
Structure of the Nanobody-Stabilized Active State of the Kappa Opioid Receptor
Che, T., Majumdar, S., Zaidi, S. A., Ondachi, P., McCorvy, J. D., Wang, S., Mosier, P. D., Uprety, R., Vardy, E., Krumm, B. E., et al. (2018) · Cell · doi:10.1016/j.cell.2017.12.011 · Cited by 365
Self-citationBreaking barriers to novel analgesic drug development
Yekkirala, A. S., Roberson, D. P., Bean, B. P., & Woolf, C. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.87 · Cited by 364
Cannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease
Kendall, D. A., & Yudowski, G. A. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00294 · Cited by 359
Opioid receptors: drivers to addiction?
Darcq, E., & Kieffer, B. L. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0028-x · Cited by 352
Corder, G., Tawfik, V. L., Wang, D., Sypek, E. I., Low, S. A., Dickinson, J. R., Sotoudeh, C., Clark, J. D., Barres, B. A., Bohlen, C. J., et al. (2017) · Nature Medicine · doi:10.1038/nm.4262 · Cited by 348
Self-citationGillis, A., Gondin, A. B., Kliewer, A., Sanchez, J., Lim, H. D., Alamein, C., Manandhar, P., Santiago, M., Fritzwanker, S., Schmiedel, F., et al. (2020) · Science Signaling · doi:10.1126/scisignal.aaz3140 · Cited by 336
Sahlgren, C., Meinander, A., Zhang, H., Cheng, F., Preis, M., Xu, C., Salminen, T. A., Toivola, D., Abankwa, D., Rosling, A., et al. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201700258 · Cited by 315
The Opioid Epidemic: Crisis and Solutions
Skolnick, P. (2018) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052534 · Cited by 307
Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment
Comer, S. D., & Cahill, C. M. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.12.005 · Cited by 302
Virtual discovery of melatonin receptor ligands to modulate circadian rhythms
Stein, R. M., Kang, H. J., McCorvy, J. D., Glatfelter, G. C., Jones, A. J., Che, T., Slocum, S., Huang, X.-P., Savych, O., Moroz, Y. S., et al. (2020) · Nature · doi:10.1038/s41586-020-2027-0 · Cited by 298
Self-citationBiased Receptor Signaling in Drug Discovery
Kenakin, T. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.016790 · Cited by 294
Kliewer, A., Schmiedel, F., Sianati, S., Bailey, A., Bateman, J. T., Levitt, E. S., Williams, J. T., Christie, M. J., & Schulz, S. (2019) · Nature Communications · doi:10.1038/s41467-018-08162-1 · Cited by 291
GPCR drug discovery: integrating solution NMR data with crystal and cryo-EM structures
Shimada, I., Ueda, T., Kofuku, Y., Eddy, M. T., & Wüthrich, K. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.180 · Cited by 279
Molecular recognition of morphine and fentanyl by the human μ-opioid receptor
Zhuang, Y., Wang, Y., He, B., He, X., Zhou, X. E., Guo, S., Rao, Q., Yang, J., Liu, J., Zhou, Q., et al. (2022) · Cell · doi:10.1016/j.cell.2022.09.041 · Cited by 273
Targeting GLP-1 receptor trafficking to improve agonist efficacy
Jones, B., Buenaventura, T., Kanda, N., Chabosseau, P., Owen, B. M., Scott, R., Goldin, R., Angkathunyakul, N., Corrêa Jr, I. R., Bosco, D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03941-2 · Cited by 272
Multidimensional Tracking of GPCR Signaling via Peroxidase-Catalyzed Proximity Labeling
Paek, J., Kalocsay, M., Staus, D. P., Wingler, L., Pascolutti, R., Paulo, J. A., Gygi, S. P., & Kruse, A. C. (2017) · Cell · doi:10.1016/j.cell.2017.03.028 · Cited by 269
D4dopamine receptor high-resolution structures enable the discovery of selective agonists
Wang, S., Wacker, D., Levit, A., Che, T., Betz, R. M., McCorvy, J. D., Venkatakrishnan, A. J., Huang, X.-P., Dror, R. O., Shoichet, B. K., et al. (2017) · Science · doi:10.1126/science.aan5468 · Cited by 261
Self-citationPsychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Imaging neurotransmitter and neuromodulator dynamics in vivo with genetically encoded indicators
Sabatini, B. L., & Tian, L. (2020) · Neuron · doi:10.1016/j.neuron.2020.09.036 · Cited by 203
Viscusi, E. R., Skobieranda, F., Soergel, D. G., Cook, E., Burt, D. A., & Singla, N. (2019) · Journal of Pain Research · doi:10.2147/jpr.s171013 · Cited by 167
Altarifi, A. A., David, B., Muchhala, K. H., Blough, B. E., Akbarali, H., & Negus, S. S. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881116689257 · Cited by 166
“This evidence for abuse liability by (+)-TRV130 contrasts with a recent report that a single dose of (±)-TRV130 failed to produce a conditioned place preference in mice (Manglik et al., 2016).”
BackgroundResultInfluentialNIDA’s medication development priorities in response to the Opioid Crisis: ten most wanted
Rasmussen, K., White, D. A., & Acri, J. B. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-018-0292-5 · Cited by 128
Algera, M. H., Kamp, J., van der Schrier, R., van Velzen, M., Niesters, M., Aarts, L., Dahan, A., & Olofsen, E. (2019) · British Journal of Anaesthesia · doi:10.1016/j.bja.2018.12.023 · Cited by 123
Averting opioid-induced respiratory depression without affecting analgesia
Dahan, A., van der Schrier, R., Smith, T., Aarts, L., van Velzen, M., & Niesters, M. (2018) · Anesthesiology · doi:10.1097/aln.0000000000002184 · Cited by 115
Discovery of new GPCR ligands to illuminate new biology
Roth, B. L., Irwin, J. J., & Shoichet, B. K. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2490 · Cited by 94
Self-citationOptimization of a series of mu opioid receptor (MOR) agonists with high G protein signaling bias
Kennedy, N. M., Schmid, C. L., Ross, N. C., Lovell, K. M., Yue, Z., Chen, Y. T., Cameron, M. D., Bohn, L. M., & Bannister, T. D. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01136 · Cited by 71
Noble, F., & Marie, N. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00742 · Cited by 56
Low Intrinsic Efficacy Alone Cannot Explain the Improved Side Effect Profiles of New Opioid Agonists
Stahl, E. L., & Bohn, L. M. (2022) · Biochemistry · doi:10.1021/acs.biochem.1c00466 · Cited by 55
Vasudevan, L., Vandeputte, M., Deventer, M., Wouters, E., Cannaert, A., & Stove, C. P. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113910 · Cited by 55
Mu-Opioid Receptor Selective Superagonists Produce Prolonged Respiratory Depression
Malcolm, N. J., Palkovic, B., Sprague, D. J., Calkins, M. M., Lanham, J. K., Halberstadt, A. L., Stucke, A. G., & McCorvy, J. D. (2023) · iScience · doi:10.1016/j.isci.2023.107121 · Cited by 53
“mediated by the same receptor that is driving the therapeutic response.(15,16) An excellent target for biased agonist drug discovery is the opioid receptors, where G protein-biased MOR-selective agonists have been developed to eliminate opioid-induced side effects, including the recently FDA-approved drug oliceridine…”
BackgroundMethodInfluentialSelf-citationG-protein–coupled receptors are dynamic regulators of digestion and targets for digestive diseases
Canals, M., Poole, D. P., Veldhuis, N. A., Schmidt, B. L., & Bunnett, N. W. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.266 · Cited by 35
Bilel, S., Azevedo Neto, J., Arfè, R., Tirri, M., Gaudio, R. M., Fantinati, A., Bernardi, T., Boccuto, F., Marchetti, B., Corli, G., et al. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109020 · Cited by 34
McPherson, K. B., Leff, E. R., Li, M.-H., Meurice, C., Tai, S., Traynor, J. R., & Ingram, S. L. (2018) · The Journal of Neuroscience · doi:10.1523/jneurosci.0516-18.2018 · Cited by 34
Focusing on the Opioid System for Addiction Biomarker Discovery
Belzeaux, R., Lalanne, L., Kieffer, B. L., & Lutz, P.-E. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.12.004 · Cited by 28
Metadata
- Authors
- Manglik, A., Lin, H., Aryal, D. K., McCorvy, J. D., Dengler, D., Corder, G., Levit, A., Kling, R. C., Bernat, V., Hübner, H., Huang, X.-P., Sassano, M. F., Giguère, P. M., Löber, S., Duan, D., Scherrer, G., Kobilka, B. K., Gmeiner, P., Roth, B. L., & Shoichet, B. K.
- Venue
- Nature
- Published
- 2016-08-17
- Volume
- 537
- Issue
- 7619
- Pages
- 185-190
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2512819857
- Cited by
- 944
- References
- 73
- FWCI
- 56.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.